Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ILiAD Selects Emmes Group to Conduct Phase III Studies of Pertussis Vaccine Candidate | Contract Pharma

What are you searching for?

Sign in
Breaking News

ILiAD Selects Emmes Group to Conduct Phase III Studies of Pertussis Vaccine Candidate

Could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

ILiAD Biotechnologies LLC, a late-stage biotech development company dedicated to the prevention of disease caused by Bordetella pertussis, has selected Emmes Group, a global contract research and technology organization, to conduct upcoming Phase III studies of its lead pertussis vaccine candidate, BPZE1.
 
ILiAD selected Emmes Group for its expertise in vaccine development, agility in managing complex clinical trials, strong local market presence, and its integrated technology capabilities. Emmes Groups’ VaxTrials unit has previously demonstrated proficiency and clinical trial excellence through its successful support of ILiAD’s Phase II IB-201P BPZE1 study.
 
Dr. Keith Rubin, CEO of ILiAD Biotechnologies, commented, “Selecting Emmes Group for our Phase III BPZE1 trials has been a carefully considered strategic decision to ensure the highest standards of clinical research. VaxTrials’ specialization in vaccines and Veridix AI’s advanced technological capabilities will be instrumental in executing our BPZE1 vaccine clinical development plan.”
 
“We are honored and pleased that ILiAD has selected Emmes Group as its partner to continue the clinical development of BPZE1. We look forward to working closely with ILiAD’s clinical development team on this promising new vaccine, which could significantly reduce the transmissibility and incidence of B. pertussis, particularly in vulnerable populations,” said Sastry Chilukuri, CEO of Emmes Group.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics